Personalized medicine is transforming how physicians diagnose and treat medical conditions. Rather than being limited to tools featuring the same therapies to treat patients with similar or specific disorders, therapies can now be tailored to the patient’s individual characteristics and needs. This opportunity includes all stages of care – prevention, diagnosis, treatment and follow-up.1 Ultimately, this custom approach enables physicians to diagnose and treat disorders more quickly and accurately, or even to prevent them before they occur.2 Personalized medicine has the potential to transform the practice of medicine, enabling health care providers to shift the emphasis from response to prevention. It can predict predisposition (or susceptibility) to certain disorders, improve detection, preempt progression, customize prevention strategies, and even reduce the time, cost, and failure rate of clinical trials.3 Central to this new medical model is the identification and detection of biomarkers, or the molecules that occur naturally in the human body. These molecules can be used to identify normal or abnormal conditions in the body, diagnose disorders or predict the likelihood of a biological disorder in the future.4
The term "biomarkers" is generally used as a reference to measurable indicators of some biological state or condition.5 Biomarkers can be used alone or in combination with other diagnostics to assess patient health or disease states.6 They can also be introduced into the body as traceable substances to help evaluate organ function or other characteristics.7 For personalized medicine, there are two types of key biomarkers.
Regulatory agencies and independent industry-affiliated organizations recognize the value of biomarkers in identifying disorders and developing therapeutics. With the emerging interest in personalized medicine, there is a high level of priority to identifying biomarkers, research tools, development methods and pathways for regulatory approval. The U.S. Food and Drug Administration (“FDA”) is uniquely positioned to play a role in fostering biomarker product development.16 They have identified key areas to quickly bring biomarkers through the development stage for therapeutic use.17Among these are:
The FDA has established the Biomarker Qualification Program to support and cooperate with scientists and clinicians in biomarker development.19 The program facilitates the movement of biomarkers through the regulatory, development and qualification processes.20 Institutions, scientists and clinicians anticipate growth in the use of biomarkers for diagnostic and therapeutic use.
There has also been remarkable domestic and international interest and growth in professional organizations, consortiums and conferences.21 22 Their goals are to further biomarker research, qualification and development. These organizations are both in the public and private sectors, and actively partner with the FDA and the Biomarker Qualification Program. By bringing together expertise and resources they hope to identify, develop and qualify potential biomarkers and influence the identification, prevention and treatment of disorders.23
The growth in biomarker research and development has resulted in their innovative use in the diagnosis and treatment of not just illnesses, but injuries as well. There are some biomarkers that can predict the likelihood of developing specific disorders even in the absence of genetic predisposition. Some examples of biomarkers and their use in detection and diagnosis include:
There could be a variety of risks emanating from the use of biomarkers. The level of the risk would vary on the application of the biomarkers. Examples include the following.
With human clinical trials for new drug products, there are specific classes of biomarkers that can indicate the toxicity of a drug molecule under development (therapeutic). The presence of these biomarkers can indicate how an organ such as a liver reacts to a specific drug molecule and also provide guidance on the level of toxicity to the liver. Such detection systems are used during the early stages of drug development (Phase 1) to filter out potentially toxic molecules. However, if the necessary biomarkers are undetected during this stage, higher toxicity drug molecules could go through to the next round of development. This failure could result in additional development costs to the drug manufacturer, giving rise to a potential errors and omissions claim against the manufacturer of the biomarker detection system. There could also be products liability losses if the failure resulted in property damage and/or bodily injury.
The manufacture or use of biomarkers may also present a safety exposure as it pertains to workers compensation exposures. Biomarkers are commonly identified and analyzed in laboratory and life sciences environments. Laboratories engaging in biomarker research, development and analysis should have employee safety as well as health programs and policies in place. These should be applicable to regulatory requirements and safety management best practices, including those specific to laboratories, such as the Federal OSHA Laboratory Safety Standard, section 1910.1450. These also include controls for chemical, biological, physical, general safety and any other exposures which employees might encounter in the laboratory workspace.
The emergence of new technologies, increasing discovery rates of novel genetic and protein-based biomarkers and new methodologies for the detection of physical biomarkers, all suggest significant clinical benefits. Advances in genomic and proteomic technologies are now allowing human diseases to be detected and diagnosed on a molecular basis, leading to customized treatment protocols. The identification and therapeutic use of biomarkers is essential to achieving a new era of predictive, preventive and targeted medicine. The ability to diagnose and treat disorders on an individual basis is limited only by researchers’ ability to identify biomarkers associated with those disorders and develop a therapeutic for their treatment.
To learn more about how OneBeacon Technology Insurance can help you manage online and other technology risks, please contact Dan Bauman, Vice President of Risk Control for OneBeacon Technology Insurance at email@example.com or 262.966.2739.
1 “The Benefits of Personalized Medicine.” The Jackson Laboratory. Accessed September 2014. http://genetichealth.jax.org/personalized-medicine/what-is/benefits.html
2 Synder, Bill & Dagny, Stuart (Summer 2011). "The Promise of Personalized Medicine." Vanderbilt Magazine. Accessed September 2014. http://www.vanderbilt.edu/magazines/vanderbilt-magazine/2011/08/the-promise-of-personalized-medicine/
3 Ibid 1
4 "NCI Dictionary of Cancer Terms." National Cancer Institute Accessed September 2014. http://www.cancer.gov/dictionary?cdrid=45618
5 Mandal, Ananya (November 17, 2013). "What is a Biomarker?" News-Medical Accessed September 2014. http://www.news-medical.net/health/Biomarker-What-is-a-Biomarker.aspx
6 Ibid 5.
7 "Biomarker." Wikipedia. Accessed September 2014. http://en.wikipedia.org/wiki/Biomarker
8 Ibid 7.
9 "Frequently Asked Questions About Genetic Testing." National Human Genome Research Institute. Accessed September 2014. http://www.genome.gov/19516567
10 "Gene Gateway - Exploring Genes and Genetics Disorders." Oak Ridge National Laboratory. Accessed September 2014. http://web.ornl.gov/sci/techresources/Human_Genome/posters/chromosome/index.shtml
11 Ibid 7.
12 "ELISA." Wikipedia. Accessed September 2014. http://en.wikipedia.org/wiki/ELISA
13 "Simoa Science." Quanterix Corporation. Accessed September 2014. http://www.quanterix.com/technology/simoa-science
14 Gupta P. D, Dave Mansai, Vasavada A. R. (July 2005) "Protein Nanotechnology — A Powerful Futuristic Diagnostic Technique." National Institute of Health. Accessed September 2014. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3453853/pdf/12291_2008_Article_BF02867400.pdf
15 "Nanotechnology-based assay for cancer proteins increases sensitivity a thousand fold." The Foresight Institute, http://www.foresight.org/nanodot/?p=2899
16 “Personalized Medicine: FDA’s Unique Role and Responsibilities in Personalized Medicine.” U.S. Food and Drug Administration. Accessed September 2014. http://www.fda.gov/scienceresearch/specialtopics/personalizedmedicine/default.htm
17 Ibid 16.
18 “Select FDA Guidance Documents That Relate to Personalized Medicine.” U.S. Food and Drug Administration. Accessed September 2014. http://www.fda.gov/ScienceResearch/SpecialTopics/PersonalizedMedicine/ucm372544.htm
19 “Biomarker Qualification Program.” U.S. Food and Drug Administration. Accessed September 2014. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284076.htm
20 Ibid 19.
21 "Biomarkers & Diagnostics World Congress 2014." Cambridge Healthtech Institute. Accessed September 2014. http://www.biomarkerworldcongress.com/
22 "10th Annual Biomarkers Congress 2015." Oxford Global Accessed September 2014. http://www.biomarkers-congress.com/
23 "Biomarkers Consortium." Foundation for the National Instututes of Health Accessed September 2014. http://www.fnih.org/what-we-do/current-research-programs/the-biomarkers-consortium
24 (June 26, 2014). "New test predicts risk of non-hereditary breast cancer." ScienceDaily. Accessed September 2014. http://www.sciencedaily.com/releases/2014/06/140626213357.htm
25 Humpel, Christian. (January 2011). "Identifying and validating biomarkers for Alzheimer's disease." National Institutes of Health. Accessed September 2014. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016495/
26 Abbott, Alison. (March 9, 2014). "Biomarkers could predict Alzheimer's before it starts." Nature. Accessed September 2014. http://www.nature.com/news/biomarkers-could-predict-alzheimer-s-before-it-starts-1.14834
27 (August 1, 2013). "GE-NFL Head Health Challenge continues." NFL.com. Accessed September 2014. http://www.nfl.com/news/story/0ap1000000223891/article/genfl-head-health-challenge-continues
28 (January 23, 2014). "Quanterix Awarded Grant from GE and the NFL’s Head Health Challenge." Quanterix Corporation Accessed September 2014. http://www.quanterix.com/events-news/press-releases/item/284-quanterix-awarded-grant-from-ge-and-the-nfl%E2%80%99s-head-health-challenge
29 Godfrey, Ashley. (September 2012). "Study finds a possible biomarker of occupational exposure in firefighters." National Institutes of Health. Accessed September 2014. http://www.niehs.nih.gov/news/newsletter/2012/9/science-biomarker/
30 Schug, Bailey. (March 2013). “Validating hair as a biomarker of manganese exposure." National Institutes of Health. Accessed September 2014. http://www.niehs.nih.gov/news/newsletter/2013/3/science-hair/index.htm